Zobrazeno 1 - 10
of 324
pro vyhledávání: '"Eudravigilance"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract In recent years, regulatory agencies have raised concerns about the presence of potentially carcinogenic substances in certain formulations of Angiotensin Receptor Blockers (ARBs). Specifically, nitrosamines and azido compounds have been ide
Externí odkaz:
https://doaj.org/article/f6e7aff0418a46d6a916ce6010eda3cd
Autor:
Atul Khurana, Syed Arman Rabbani, Mohamed El-Tanani, Mandeep Kumar Arora, Shrestha Sharma, Harikesh Dubey, Alaa A. Aljabali, Murtaza M. Tambuwala
Publikováno v:
Clinical Epidemiology and Global Health, Vol 30, Iss , Pp 101805- (2024)
Background: Tirzepatide has demonstrated superior efficacy in glycemic control and weight reduction compared to existing GLP-1 receptor agonists. However, its safety profile remains to be fully elucidated in real-world settings. This study examines i
Externí odkaz:
https://doaj.org/article/c7be2d7654984122a6fcce9dac0f04f9
Autor:
Michael Magdy Fahmy Girgis, Gergely Farkasinszky, Klára Fekete, István Fekete, Miklós Vecsernyés, Ildikó Bácskay, László Horváth
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Epilepsy is a widespread disease requiring long-term drug treatment. The aim of this study was to collect information on reported suspected adverse drug reactions (sADRs) of antiseizure medications (ASMs) and study their seriousness and
Externí odkaz:
https://doaj.org/article/d0b5af69826646cf8a139b47e84ef414
Autor:
Ilaria Ammendolia, Maria Sframeli, Emanuela Esposito, Luigi Cardia, Alberto Noto, Mariaconcetta Currò, Gioacchino Calapai, Maria De Pasquale, Carmen Mannucci, Fabrizio Calapai
Publikováno v:
Pharmaceuticals, Vol 17, Iss 11, p 1513 (2024)
Background/Objectives: Neuronal Ceroid Lipofuscinosis type 2 is a rare pathology affecting mainly the central nervous system (CNS) and retina, and is caused by variants in the gene encoding the lysosomal enzyme tripeptidyl peptidase 1. Therapy with e
Externí odkaz:
https://doaj.org/article/62c331643af440fb81f390d3cef0e195
Autor:
Cristina Scavone, Antonietta Anatriello, Isabella Baccari, Andrea Cantone, Daniele Di Giulio Cesare, Francesca Futura Bernardi, Ornella Moreggia, Valerio Liguori, Vincenzo Andreone, Giorgia Teresa Maniscalco, Annalisa Capuano
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
IntroductionIn 2021 ofatumumab, a recombinant human anti-CD20 monoclonal antibody (mAb) already authorized for the treatment of chronic lymphocytic leukemia, received the marketing approval for the treatment of relapsing forms of multiple sclerosis (
Externí odkaz:
https://doaj.org/article/6e8f6ecdf90846e894bfbccc0a7fd25e
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6533-6545 (2023)
Poly (ADP-Ribose) polymerase inhibitors (PARPi) have emerged as a targeted therapy in cancer treatment with promising results in various types of cancer. This work aims to investigate the profile of adverse drug reactions (ADRs) associated with PARPi
Externí odkaz:
https://doaj.org/article/92778d686a7d4536be4e3f05251cb68e
Autor:
Fabrizio Calapai, Carmen Mannucci, Mariaconcetta Currò, Luigi Cardia, Emanuela Esposito, Gioacchino Calapai, Ilaria Ammendolia
Publikováno v:
Pharmaceuticals, Vol 17, Iss 3, p 364 (2024)
Background: Evolocumab is a humanized immunoglobulin G2 monoclonal antibody, directed against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), prescribed in hypercholesterolemic patients. The safety profile of this drug is currently defined by
Externí odkaz:
https://doaj.org/article/c7ba84b4c2c047f5864da24ad8fd6d86
Autor:
Bogdan Ioan Vintila, Anca Maria Arseniu, Claudiu Morgovan, Anca Butuca, Victoria Bîrluțiu, Carmen Maximiliana Dobrea, Luca Liviu Rus, Steliana Ghibu, Alina Simona Bereanu, Rares Arseniu, Ioana Roxana Codru, Mihai Sava, Felicia Gabriela Gligor
Publikováno v:
Antibiotics, Vol 13, Iss 2, p 144 (2024)
Clostridioides difficile is a Gram-positive bacteria that causes nosocomial infections, significantly impacting public health. In the present study, we aimed to describe the clinical characteristics, outcomes, and relationship between antibiotic expo
Externí odkaz:
https://doaj.org/article/f429e19423d94fc9bdaabed380b40d61
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.